Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an...

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Acute coronary syndromes (ACS) often require early invasive approaches, but many patients receive medical management after initial assessment.
• Predicting adverse cardiac events in medically treated ACS patients is crucial for optimizing care.

Purpose of the Study:

• To identify predictors of adverse cardiac events in patients with ACS managed medically after angiographic triage.
• To compare antithrombotic strategies regarding bleeding and ischemic outcomes in this population.

Main Methods:

• Analysis of a substudy from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, including 4491 ACS patients on medical management.
• Comparison of bleeding and composite ischemic events (death, myocardial infarction, revascularization) among three antithrombotic treatment arms: bivalirudin monotherapy, bivalirudin plus glycoprotein IIb/IIIa inhibitors, and heparin plus glycoprotein IIb/IIIa inhibitors.

Main Results:

• Bivalirudin-based therapies significantly reduced major bleeding at 30 days compared to heparin with glycoprotein IIb/IIIa inhibitors.
• Composite ischemic events at 1 year were similar across all three treatment groups.
• Independent predictors of composite ischemia included angiographic factors like jeopardy score and coronary ectasia, and at 1 year, previous percutaneous coronary intervention and number of diseased vessels.

Conclusions:

• Bivalirudin therapy in medically managed ACS patients reduced bleeding complications without compromising 1-year ischemic outcomes compared to heparin.
• Angiographic parameters, rather than traditional clinical factors, were the strongest predictors of ischemic outcomes.
• Early angiographic screening is supported for moderate- to high-risk ACS patients treated medically.